Company Overview - Sionna Therapeutics has a market capitalization of $1.62 billion and a net income of -$70.68 million for the trailing twelve months (TTM) [4] - The company's stock has experienced a 1-year price change of 45.36%, calculated using January 12, 2025, as the reference date [4] Insider Transactions - On December 5, 2025, Chief Legal Officer Jennifer Fitzpatrick exercised 10,250 options and sold the resulting shares for a total transaction value of $415,330, with a weighted average purchase price of $40.52 per share [1][2] - Following this transaction, Fitzpatrick holds no directly owned shares but retains 61,185 outstanding options, which may provide future exposure contingent on vesting and exercise conditions [6] Market Performance - The shares were sold at a price modestly above the market close of $40.29 on December 5, 2025, and the current price as of January 12, 2026, is $36.34 [6] - The company has been active in insider transactions, with at least five different insiders conducting transactions recently [8] Business Focus - Sionna Therapeutics specializes in researching and developing pharmaceutical medicine targeting cystic fibrosis, with no current revenue but potential revenue from future product commercialization or licensing [7] - The company is optimistic about its clinical strategies to combat cystic fibrosis and claims to have strong financial support for development through 2028 [9]